Overview
Vandetanib is a small-molecule tyrosine kinase inhibitor developed by AstraZeneca and approved by the FDA in 2011 under the brand name Caprelsa. It is specifically indicated for the treatment of symptomatic or aggressive medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. The drug selectively inhibits RET kinase, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR), disrupting critical signaling pathways in tumor growth and angiogenesis. As an orphan drug, vandetanib addresses a niche oncology market. Its development marked a significant advancement for MTC patients with limited treatment options. The drug is administered orally in tablet form, typically at a daily dose of 300 mg, with strict monitoring required due to potential cardiovascular and dermatological side effects.
Physical and Chemical Properties
Vandetanib is a white to off-white crystalline powder with a molecular weight of 475.36 g/mol. It is sparingly soluble in aqueous solutions but demonstrates better solubility in organic solvents like DMSO, which is often used in preclinical studies. The compound exhibits stability under recommended storage conditions (2-8°C), though prolonged exposure to light or moisture should be avoided. Chemically, vandetanib contains a quinazoline core structure with bromine and fluorine substitutions, contributing to its kinase-binding affinity. Its melting point ranges between 160-165°C, consistent with typical small-molecule pharmaceuticals. Analytical characterization commonly employs HPLC and mass spectrometry to verify purity, which must exceed 98% for clinical use.
Main Applications
Vandetanib's primary application is the treatment of metastatic or unresectable medullary thyroid cancer (MTC), particularly in cases with RET mutations. Clinical trials demonstrated a progression-free survival benefit, leading to its approval as a monotherapy. The drug is also under investigation for other RET-driven cancers, including non-small cell lung cancer and colorectal cancer, though these are off-label uses. In MTC, vandetanib targets the RET proto-oncogene, which is mutated in approximately 50% of hereditary cases and 10% of sporadic cases. By concurrently inhibiting VEGFR and EGFR, it reduces tumor vascularization and cell proliferation. Its use requires genetic testing to confirm RET status, and treatment response is monitored through imaging and calcitonin level assessments.
Safety and Storage
Vandetanib carries a black box warning for QT interval prolongation, which can lead to life-threatening arrhythmias like torsades de pointes. Electrolyte monitoring (potassium, calcium, magnesium) and baseline ECG are mandatory before initiation. Other risks include severe skin reactions (e.g., Stevens-Johnson syndrome), hypertension, and embryofetal toxicity. It is classified as Pregnancy Category D. Proper storage necessitates refrigeration (2-8°C) in original packaging to prevent degradation. Handling should follow cytotoxic drug protocols, including gloves and protective eyewear. Accidental exposure requires immediate decontamination. Institutional guidelines often mandate specialized training for personnel dispensing vandetanib due to its narrow therapeutic index.
B2B Procurement Guide
Procuring vandetanib active pharmaceutical ingredient (API) demands stringent verification of supplier credentials. Prioritize vendors with FDA/EMA-approved GMP facilities and audited quality control systems. Documentation should include certificates of analysis (CoA), impurity profiles, and stability data. Bulk pricing varies significantly based on quantity (e.g., $10,000-$15,000 per 100 mg), with contracts often negotiated directly with manufacturers. Given its niche application, lead times may extend to several months. Import/export compliance is critical, as vandetanib is regulated as a prescription drug globally. Consider partnering with logistics providers experienced in cold-chain transport for biologics. For formulation development, excipient compatibility studies are recommended due to the drug's poor aqueous solubility.
Related Manufacturers
- 主营：抑制剂、化合物库、药物筛选、天然产物
- 主营：白蜡树素、百两金素、半齿泽兰素
- 主营：实验试剂、工具化合物、抗体抑制剂、重组蛋白